| Stem cell gene expression programs influence clinical outcome in human leukemia K Eppert, K Takenaka, ER Lechman, L Waldron, B Nilsson, P Van Galen, ... Nature medicine 17 (9), 1086-1093, 2011 | 1168 | 2011 |
| IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia … G Marcucci, K Maharry, YZ Wu, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 28 (14), 2348-2355, 2010 | 974 | 2010 |
| A 17-gene stemness score for rapid determination of risk in acute leukaemia SWK Ng, A Mitchell, JA Kennedy, WC Chen, J McLeod, N Ibrahimova, ... Nature 540 (7633), 433-437, 2016 | 782 | 2016 |
| Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia KH Metzeler, T Herold, M Rothenberg-Thurley, S Amler, MC Sauerland, ... Blood, The Journal of the American Society of Hematology 128 (5), 686-698, 2016 | 580 | 2016 |
| Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, ... Journal of clinical oncology 30 (36), 4515-4523, 2012 | 518 | 2012 |
| An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia KH Metzeler, M Hummel, CD Bloomfield, K Spiekermann, J Braess, ... Blood 112 (10), 4193-4201, 2008 | 454 | 2008 |
| TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study KH Metzeler, K Maharry, MD Radmacher, K Mrózek, D Margeson, ... Journal of clinical oncology 29 (10), 1373-1381, 2011 | 436 | 2011 |
| Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical … A Dufour, F Schneider, KH Metzeler, E Hoster, S Schneider, E Zellmeier, ... Journal of clinical oncology 28 (4), 570-577, 2010 | 380 | 2010 |
| ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category KH Metzeler, H Becker, K Maharry, MD Radmacher, J Kohlschmidt, ... Blood, The Journal of the American Society of Hematology 118 (26), 6920-6929, 2011 | 351 | 2011 |
| Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia G Marcucci, KH Metzeler, S Schwind, H Becker, K Maharry, K Mrózek, ... Journal of clinical oncology 30 (7), 742-750, 2012 | 347 | 2012 |
| RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene … JH Mendler, K Maharry, MD Radmacher, K Mrózek, H Becker, ... Journal of clinical oncology 30 (25), 3109-3118, 2012 | 340 | 2012 |
| Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, ... Leukemia 33 (1), 64-74, 2019 | 267 | 2019 |
| FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with … SP Whitman, K Maharry, MD Radmacher, H Becker, K Mrózek, ... Blood, The Journal of the American Society of Hematology 116 (18), 3622-3626, 2010 | 267 | 2010 |
| Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism C Krupka, P Kufer, R Kischel, G Zugmaier, FS Lichtenegger, T Köhnke, ... Leukemia 30 (2), 484-491, 2016 | 263 | 2016 |
| DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic, CD Bloomfield, ... Leukemia 26 (5), 1106-1107, 2012 | 243 | 2012 |
| Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study S Schwind, K Maharry, MD Radmacher, K Mrózek, KB Holland, ... Journal of clinical oncology 28 (36), 5257-5264, 2010 | 231 | 2010 |
| CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330 C Krupka, P Kufer, R Kischel, G Zugmaier, J Bögeholz, T Köhnke, ... Blood, The Journal of the American Society of Hematology 123 (3), 356-365, 2014 | 229 | 2014 |
| Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients G Marcucci, KS Maharry, KH Metzeler, S Volinia, YZ Wu, K Mrózek, ... Journal of clinical oncology 31 (17), 2086-2093, 2013 | 215 | 2013 |
| Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia T Herold, M Rothenberg-Thurley, VV Grunwald, H Janke, D Goerlich, ... Leukemia 34 (12), 3161-3172, 2020 | 196 | 2020 |
| Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis T Herold, S Schneider, KH Metzeler, M Neumann, L Hartmann, ... haematologica 102 (1), 130, 2017 | 174 | 2017 |
Guido MarcucciCity of Hope在 coh.org 的电子邮件经过验证
